Nirmatrelvir treatment of SARS‐CoV‐2‐infected mice blunts antiviral adaptive immune responses
EMBO Molecular Medicine · 2023
DOI: 10.15252/emmm.202317580 ↗Kurz gefasst
Fachartikel in der Zeitschrift EMBO Molecular Medicine, 2023. Verfasst von Valeria Fumagalli und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, Antiviral Agents, Adaptive Immunity, Lactams. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Ministero della Salute.
Abstract (Originalsprache)
Alongside vaccines, antiviral drugs are becoming an integral part of our response to the SARS‐CoV‐2 pandemic. Nirmatrelvir—an orally available inhibitor of the 3‐chymotrypsin‐like cysteine protease—has been shown to reduce the risk of progression to severe COVID‐19. However, the impact of nirmatrelvir treatment on the development of SARS‐CoV‐2‐specific adaptive immune responses is unknown. Here, by using mouse models of SARS‐CoV‐2 infection, we show that nirmatrelvir administration blunts the development of SARS‐CoV‐2‐specific antibody and T cell responses. Accordingly, upon secondary challenge, nirmatrelvir‐treated mice recruited significantly fewer memory T and B cells to the infected lungs and mediastinal lymph nodes, respectively. Together, the data highlight a potential negative impact of nirmatrelvir treatment with important implications for clinical management and might help explain the virological and/or symptomatic relapse after treatment completion reported in some individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- INGM - Istituto Nazionale di Genetica Molecolare "Romeo ed Erica Invernizzi", Milan, Italy.
- Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy.
- Dipartimento di Scienze della Vita e dell'Ambiente, Cittadella Universitaria di Monserrato, Cagliari, Italy.
ORCID-Profile: Valeria Fumagalli, Lorena Donnici, Irina Stefanelli, Francesca Esposito, Donato Inverso, Stanley Perlman, Enzo Tramontano, Raffaele De Francesco, Vincenzo Summa, Luca G Guidotti, Matteo Iannacone
Förderung
- NIAID NIH HHS
- Ministero della Salute
Zitieren
APA
Fumagalli, V., Di Lucia, P., Ravà, M., Marotta, D., Bono, E., Grassi, S., Donnici, L., Cannalire, R., Stefanelli, I., Ferraro, A., Esposito, F., Pariani, E., Inverso, D., Montesano, C., Delbue, S., Perlman, S., Tramontano, E., De Francesco, R., Summa, V., …, & Iannacone, M. (2023). Nirmatrelvir treatment of SARS‐CoV‐2‐infected mice blunts antiviral adaptive immune responses. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202317580
Vancouver
Fumagalli V, Di Lucia P, Ravà M, Marotta D, Bono E, Grassi S, et al. Nirmatrelvir treatment of SARS‐CoV‐2‐infected mice blunts antiviral adaptive immune responses. EMBO Molecular Medicine. 2023. doi:10.15252/emmm.202317580
BibTeX
@article{Fumagalli2023,
author = {Fumagalli, Valeria and Di Lucia, Pietro and Ravà, Micol and Marotta, Davide and Bono, Elisa and Grassi, Stefano and Donnici, Lorena and Cannalire, Rolando and Stefanelli, Irina and Ferraro, Anastasia and Esposito, Francesca and Pariani, Elena and Inverso, Donato and Montesano, Camilla and Delbue, Serena and Perlman, Stanley and Tramontano, Enzo and De Francesco, Raffaele and Summa, Vincenzo and Guidotti, Luca G and Iannacone, Matteo},
title = {Nirmatrelvir treatment of SARS‐CoV‐2‐infected mice blunts antiviral adaptive immune responses},
journal = {EMBO Molecular Medicine},
year = {2023},
doi = {10.15252/emmm.202317580}
}
EUVIMED